Monday, April 30, 2018

OJAS Eye Hospital brings Lumenis M22 Optimal Pulse Technology (OPT)


 Mumbai’s renowned super specialty eye care Ojas Eye Hospital, offering unmatched eye care, has brought home Lumenis  M22 Optimal Pulse Technology (OPT) for treatment of dry eyes. The latest eye care technology is a great revolutionary value addition to the ophthalmic applications especially for the treatment of dry eye.

Lumenis is the world’s largest energy-based medical device company and is renowned for technological breakthroughs ophthalmic lasers and a long list of industry gold standards.

M22 is the answer to a majority of eye inflammation treatments with OPT being the most advanced IPL technology, developed by World’s Largest Energy based medical device company, Lumenis.  Designed and curated to deliver reliable, safe and enhanced physician and patient comfort, the M22 services will be available at Ojas Eye Hospitals at Bandra and Kandivali.

Commenting on the development, Dr. Niteen Dedhia, Medical Director, OJAS Eye Hospital said “M22 is a latest state of the art eye care technology. Most recent case studies and researches have showcased prevalence of dry eye among patients ranging across age groups. The introduction of M22 OPT technology will be a path breaker and a great relief to patients who have been prescribed to eye drops, the only available solution to treat dryness.”

Adding to his statement acclaimed eye surgeon, Dr. Dedhia also said that “Getting M22 OPT to our patients is a mission-driven consortium to bring the best in eye care to the people of Western India especially Mumbai. We are looking at this as a solution and step forward to our institution Ojas’ vision to be a Globally Recognized Eye Care Hospital known for its Distinctive Excellence & Patient Satisfaction.”

“Our path breaking technology will help address the growing dry eye disease among thousands of people,” said Mr. Dharmendra Mistry, Country Head of Lumenis India, “We are happy to partner with Dr. Niteen Dedhia, who is a veteran ophthalmologist and medical director at OJAS Eye Hospital. Entering in the western market is part of our expansion strategy ensuring the increasing number of patients who will be benefited from our latest OPT technology,” he said.

Meibomian Gland dysfunction (MGD) is one of the leading causes of dry eye disease (DED), affecting millions of people worldwide. Optimal pulse technology from Lumenis has emerged as the most effective alternative for patients, leading to significant improvement in ocular surface quality, gland function and dry eye symptoms.

The Lumenis M22 OPT is an excellent technology for treating eyelid inflammation. OPT is selectively absorbed in the hemoglobin of abnormal blood vessels, and destroys them by thrombolysis. A major source of inflammation threatening the eyelids is then removed. It treats the root cause of the problem, provides immediate relief, a safe and comfortable, fast ‘lunch time treatment’ and improves the skin appearance too.     
  
Studies show that humans generally blink about 22 times a minute. But when we concentrate on a computer screen or a smart phone or even while driving, the rate goes down to five or seven blinks per minute. If this tear film does not spread sufficiently across the eye, it can lead to dryness and irritation. Experts say dry eye affects millions of adults. The risk increases with advancing age.

Lumenis is the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF).

For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods.

Ojas Eye Hospitals has been the pioneer of eye care since it began its journey in Ophthalmic Eye Care on 7th June 1987. The team of medical practitioners under the guidance of world renowned Ophthalmologist, Dr. Niteen Dedhia has been pivotal in etching a prestigious name for itself in the genre of eye care.  For more than two decades now, Ojas has emerged as a leading ophthalmic centre in Mumbai & India with more than 1,20,000 satisfied patients across India and the world.

 Dr. Dedhia has been a pioneer in performing LASIK surgery; being amongst the first to perform microkeratome LASIK as well as blade-free (Intralase femtosecond) LASIK in the country. He is also among the first to bring Phakic Intra-ocular lenses to India, providing respite to patients with very high myopia. Under his mentorship, Ojas Eye Hospital today is synonymous with superior level eye care infrastructure delivering excellent and advance technology eye care with dedication and commitment for the overall wellbeing of patient.

The M22 services and treatment are available at two branches of Ojas Eye Hospitals -

Ojas Eye Hospital
Roseland Building, Junction of Linking Road and
Waterfield Road, Bandra,
Mumbai- 400050.

Ojas Eye Hospital
Jivala Pada Road,
Behind Gokul Corcord Tower,
Thakur Village,off Western Express Highway,
Kandivali ( East)
Mumbai – 400 101

No comments:

Post a Comment